Second Genome
PrivateLast Round
M&A
Jan 2, 2024
Total Funding Raised
$99.76M
Company Overview
Second Genome operates in Healthcare & Life Sciences and is based in South San Francisco, California. Its latest recorded funding round was a Corporate Funding round in April 2020.
Second Genome is a biotechnology company that utilizes a microbiome data platform to extract microbial genetic insights for the development of precision therapies and biomarkers.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Healthcare Analytics
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Second Genome Comparables
Compare Second Genome with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Enterome | 82% | |
| Holobiome | 81% | |
| Persephone Biosciences | 79% |
For institutional investors. Book with your work email.
Second Genome Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| M&A | Jan 2, 2024 | ||||
| Corporate Funding | Apr 6, 2020 | ||||
| Grant | Sep 1, 2019 | ||||
| Grant | Jul 1, 2017 | ||||
| Series B Extension | Jul 13, 2016 | ||||
Series B | Apr 20, 2016 |
For institutional investors. Book with your work email.
Second Genome Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Roche Venture Fund | Series B |
| Digitalis Ventures | Series B, Series B Extension |
| Schroder Adveq | Series B |
| NIH RADx | Grant |
| Wavepoint Ventures | Seed, Series A Extension |
| Lifeforce Capital | Series B |
| Seraph Group | Series B, Series A Extension, Seed |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 2, 2024
Completed an M&A funding round.
- Sep 1, 2019
$967K grant received from NIH RADx.
For institutional investors. Book with your work email.
Second Genome Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Second Genome's valuation, stock price, and market status.
Is Second Genome a public or private company?
Second Genome is a private company.
What is the current stock price of Second Genome?
Second Genome is a private company, so its shares have no public market price. Caplight tracks Second Genome's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Second Genome worth (valuation)?
Valuation information for Second Genome is not publicly available.
Can I buy Second Genome stock?
Second Genome shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Second Genome's last funding round?
Second Genome's most recent funding round was M&A on January 2, 2024.
Who are the main investors in Second Genome?
Key investors in Second Genome include Roche Venture Fund, NIH RADx, Wavepoint Ventures, Roche Venture Fund, Advanced Technology Ventures.
Will Second Genome IPO soon?
No public IPO plans have been announced for Second Genome.
How can I track Second Genome secondary market activity?
Caplight tracks bids, offers, and trades in Second Genome's shares on secondary markets.